<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01143272</url>
  </required_header>
  <id_info>
    <org_study_id>BNI-2009-01</org_study_id>
    <secondary_id>2009-017374-20</secondary_id>
    <secondary_id>ISRCTN01005546</secondary_id>
    <secondary_id>DRKS00000084</secondary_id>
    <nct_id>NCT01143272</nct_id>
  </id_info>
  <brief_title>Probiotic Saccharomyces Boulardii for the Prevention of Antibiotic-associated Diarrhoea</brief_title>
  <acronym>SacBo</acronym>
  <official_title>Saccharomyces Boulardii for the Prevention of Antibiotic-associated Diarrhoea - Randomised, Double-blind, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bernhard Nocht Institute for Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Federal Ministry of Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bernhard Nocht Institute for Tropical Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      When patients in hospitals receive antibiotics they often develop diarrhoea. The consequences
      may be grave for the patient. Thus far, no preventive measure is available. The investigators
      hypothesize that the apathogenic yeast Saccharomyces boulardii, administered in addition to
      the antibiotic, may prevent episodes of diarrhoea or may lead to less pronounced diarrhoea.
      To test this hypothesis, the investigators are carrying out a clinical trial in 1520 adult
      patients in several hospitals.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Antibiotic-associated diarrhoea (AAD) is a frequent condition in hospitalised patients
      receiving antibiotic treatment. The same is true for Clostridium difficile-associated
      diarrhoea (CDAD) with even more grave consequences of increased morbidity and mortality. The
      development and evaluation of preventive strategies is one key public health challenge. In
      the absence of clinically evaluated alternatives, probiotics have been suggested to be
      beneficial for the prevention of AAD and CDAD. However, data have so far been inconclusive
      and recently published meta-analyses strongly recommended large state-of-the-art clinical
      trials on probiotic substances for the prevention of AAD and CDAD. Since the efficacy,
      side-effects and modes of action of different probiotic bacteria and yeast are strain
      specific, benefits and risks cannot be generalised. The non-pathogenic yeast Saccharomyces
      cerevisiae var. boulardii (Sac. boulardii) is considered the most promising probiotic
      substance for the prevention of AAD and CDAD. We carry out a randomised, placebo controlled,
      double blind multicentre clinical trial to evaluate Sac. boulardii for the indication of
      prevention of AAD and CDAD in 1520 adult, hospitalised patients.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Masked independent interim analysis: completion of the trial was unlikely.
  </why_stopped>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Number of Antibiotic-associated Diarrhea Episodes</measure>
    <time_frame>29 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Number of Clostridium Difficile-associated Diarrhea Episodes</measure>
    <time_frame>29 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Antibiotic-associated Diarrhea Episodes Without Evidence of Clostridium Difficile (Toxins)</measure>
    <time_frame>29 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence Density of Antibiotic-associated Diarrhea</measure>
    <time_frame>29 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Duration of Antibiotic-associated Diarrhoea and Clostridium Difficile-associated Diarrhea</measure>
    <time_frame>29 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Number of Bowel Movements in Patients With Antibiotic-associated Diarrhoea and Clostridium Difficile-associated Diarrhea</measure>
    <time_frame>29 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Discontinuation or Change of Initially Prescribed Antibiotic</measure>
    <time_frame>29 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">477</enrollment>
  <condition>Antibiotic-associated Diarrhea</condition>
  <condition>Clostridium Difficile</condition>
  <condition>Diarrhea</condition>
  <arm_group>
    <arm_group_label>Saccharomyces boulardii</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received Saccharomyces boulardii 250 mg capsules twice per day within 24 hours of initiating antibiotic treatment and continued treatment for 7 days after antibiotic discontinuation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Microcristallin cellulose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received matching placebo twice per day within 24 hours of initiating antibiotic treatment and continued treatment for 7 days after antibiotic discontinuation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saccharomyces boulardii</intervention_name>
    <description>Units: 500 mg per day Route of administration : Oral Use Hard-Capsule</description>
    <arm_group_label>Saccharomyces boulardii</arm_group_label>
    <other_name>Perenterol® Forte</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Microcristallin cellulose</arm_group_label>
    <other_name>Microcristallin cellulose</other_name>
    <other_name>Matching capsules containing no active ingredients</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult patient (≥ 18 years)

          -  patient hospitalized

          -  patient receives systemic antibiotic treatment

          -  patient contractually capable

          -  patient able to follow study procedures

          -  informed consent of patient

        Exclusion Criteria:

          -  allergy against yeast and/or Perenterol® forte und/oder placebos containing
             Saccharomyces cerevisiae HANSEN CBS 5926, lactose-monohydrate, magnesium stearate,
             gelatine, sodium dodecyl sulfate, titan dioxide, microcrystalline cellulose.

          -  central venous catheter

          -  immunosuppression

          -  diarrhoea and/or chronic diarrhoea

          -  regular intake of Perenterol®, Perenterol® forte oder Yomogi® in the last seven days
             before the start of the study

          -  systemic antimycotic treatment

          -  systemic antibiotic treatment within the last 6 weeks

          -  no protection against conception, pregnancy, or lactation

          -  simultaneous participation in other clinical trials
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan Ehrhardt, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abteilung Innere Medizin, Bundeswehrkrankenhaus Ulm</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Würtemberg</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Innere Medizin, Abteilung für Tropenmedizin und Infektionskrankheiten, Universitätsklinikum Rostock</name>
      <address>
        <city>Rostock</city>
        <state>Mecklenburg-Vorpommern</state>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakoniekrankenhaus Rotenburg (Wümme) gGmbH, Zentrum für Pneumologie</name>
      <address>
        <city>Rotenburg</city>
        <state>Niedersachsen</state>
        <zip>27356</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Knappschaftskrankenhaus Bottrop, Medizinische Klinik</name>
      <address>
        <city>Bottrop</city>
        <state>Nordrhein-Westfalen</state>
        <zip>46242</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abteilung Akut-Geriatrie, Ev. Krankenhaus Bethanien Iserlohn</name>
      <address>
        <city>Iserlohn</city>
        <state>Nordrhein-Westfalen</state>
        <zip>58644</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Vest GmbH, Behandlungszentrum Paracelsus-Klinik Marl</name>
      <address>
        <city>Marl</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45770</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>I. Medizinische Klinik und Poliklinik, Johannes-Gutenberg-Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Saarbrücken</name>
      <address>
        <city>Saarbrücken</city>
        <state>Saarland</state>
        <zip>66119</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum St.Georg, Klinik für Infektiologie, Tropenmedizin und Nephrologie</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04129</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abt. Innere Medizin, Krankenhaus Reinbek, St. Adolf -Stift</name>
      <address>
        <city>Reinbek</city>
        <state>Schleswig-Holstein</state>
        <zip>21465</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Bremen Ost, Klinik für Innere Medizin</name>
      <address>
        <city>Bremen</city>
        <zip>28325</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>I. Medizinische Klinik und Poliklinik, Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Agaplesion Diakonieklinikum Hamburg, Klinik für Innere Medizin</name>
      <address>
        <city>Hamburg</city>
        <zip>20259</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bethesda Krankenhaus Bergedorf, Klinik für Innere Medizin</name>
      <address>
        <city>Hamburg</city>
        <zip>21029</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.bni-hamburg.de</url>
    <description>Sponsor website</description>
  </link>
  <link>
    <url>http://www.clinicaltrial-sacbo.de</url>
    <description>Clinical trial website</description>
  </link>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2010</study_first_submitted>
  <study_first_submitted_qc>June 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2010</study_first_posted>
  <results_first_submitted>March 17, 2016</results_first_submitted>
  <results_first_submitted_qc>June 7, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 18, 2016</results_first_posted>
  <last_update_submitted>June 7, 2016</last_update_submitted>
  <last_update_submitted_qc>June 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bernhard Nocht Institute for Tropical Medicine</investigator_affiliation>
    <investigator_full_name>Stephan Ehrhardt</investigator_full_name>
    <investigator_title>Lead investigator</investigator_title>
  </responsible_party>
  <keyword>antibiotic</keyword>
  <keyword>associated</keyword>
  <keyword>diarrhoea</keyword>
  <keyword>saccharomyces boulardii</keyword>
  <keyword>Antibiotic-associated diarrhoea (AAD)</keyword>
  <keyword>Clostridium difficile-associated-diarrhoea (CDAD)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Saccharomyces Boulardii</title>
          <description>Participants received Saccharomyces boulardii 250 mg capsules twice per day within 24 hours of initiating antibiotic treatment and continued treatment for 7 days after antibiotic discontinuation
Saccharomyces boulardii: Units: 500 mg per day Route of administration : Oral Use Hard-Capsule</description>
        </group>
        <group group_id="P2">
          <title>Microcristallin Cellulose</title>
          <description>Participants received matching placebo twice per day within 24 hours of initiating antibiotic treatment and continued treatment for 7 days after antibiotic discontinuation
Placebo: Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="246"/>
                <participants group_id="P2" count="231"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="246"/>
                <participants group_id="P2" count="231"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Saccharomyces Boulardii</title>
          <description>Participants received Saccharomyces boulardii 250 mg capsules twice per day within 24 hours of initiating antibiotic treatment and continued treatment for 7 days after antibiotic discontinuation
Saccharomyces boulardii: Units: 500 mg per day Route of administration : Oral Use Hard-Capsule</description>
        </group>
        <group group_id="B2">
          <title>Microcristallin Cellulose</title>
          <description>Participants received matching placebo twice per day within 24 hours of initiating antibiotic treatment and continued treatment for 7 days after antibiotic discontinuation
Placebo: Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="246"/>
            <count group_id="B2" value="231"/>
            <count group_id="B3" value="477"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.1" spread="16.5"/>
                    <measurement group_id="B2" value="56.5" spread="17.8"/>
                    <measurement group_id="B3" value="58.4" spread="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                    <measurement group_id="B2" value="129"/>
                    <measurement group_id="B3" value="269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="246"/>
                    <measurement group_id="B2" value="231"/>
                    <measurement group_id="B3" value="477"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="171.8" spread="9.4"/>
                    <measurement group_id="B2" value="171.7" spread="10.0"/>
                    <measurement group_id="B3" value="171.7" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83.1" spread="17.0"/>
                    <measurement group_id="B2" value="83.0" spread="18.1"/>
                    <measurement group_id="B3" value="83.0" spread="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.1" spread="5.2"/>
                    <measurement group_id="B2" value="28.1" spread="5.6"/>
                    <measurement group_id="B3" value="28.1" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>C-reactive protein (CRP)</title>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.0" spread="89.3"/>
                    <measurement group_id="B2" value="72.2" spread="98.9"/>
                    <measurement group_id="B3" value="71.6" spread="93.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Leukocyte count</title>
          <units>10^9 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.3" spread="4.6"/>
                    <measurement group_id="B2" value="11.4" spread="6.7"/>
                    <measurement group_id="B3" value="10.8" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Number of Antibiotic-associated Diarrhea Episodes</title>
        <time_frame>29 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Saccharomyces Boulardii</title>
            <description>Participants received Saccharomyces boulardii 250 mg capsules twice per day within 24 hours of initiating antibiotic treatment and continued treatment for 7 days after antibiotic discontinuation
Saccharomyces boulardii: Units: 500 mg per day Route of administration : Oral Use Hard-Capsule</description>
          </group>
          <group group_id="O2">
            <title>Microcristallin Cellulose</title>
            <description>Participants received matching placebo twice per day within 24 hours of initiating antibiotic treatment and continued treatment for 7 days after antibiotic discontinuation
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Antibiotic-associated Diarrhea Episodes</title>
          <units>Episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="246"/>
                <count group_id="O2" value="231"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.94</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>1.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.25</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.87</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Clostridium Difficile-associated Diarrhea Episodes</title>
        <time_frame>29 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Saccharomyces Boulardii</title>
            <description>Participants received Saccharomyces boulardii 250 mg capsules twice per day within 24 hours of initiating antibiotic treatment and continued treatment for 7 days after antibiotic discontinuation
Saccharomyces boulardii: Units: 500 mg per day Route of administration : Oral Use Hard-Capsule</description>
          </group>
          <group group_id="O2">
            <title>Microcristallin Cellulose</title>
            <description>Participants received matching placebo twice per day within 24 hours of initiating antibiotic treatment and continued treatment for 7 days after antibiotic discontinuation
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Clostridium Difficile-associated Diarrhea Episodes</title>
          <units>episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="246"/>
                <count group_id="O2" value="231"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Antibiotic-associated Diarrhea Episodes Without Evidence of Clostridium Difficile (Toxins)</title>
        <time_frame>29 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Saccharomyces Boulardii</title>
            <description>Participants received Saccharomyces boulardii 250 mg capsules twice per day within 24 hours of initiating antibiotic treatment and continued treatment for 7 days after antibiotic discontinuation
Saccharomyces boulardii: Units: 500 mg per day Route of administration : Oral Use Hard-Capsule</description>
          </group>
          <group group_id="O2">
            <title>Microcristallin Cellulose</title>
            <description>Participants received matching placebo twice per day within 24 hours of initiating antibiotic treatment and continued treatment for 7 days after antibiotic discontinuation
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Antibiotic-associated Diarrhea Episodes Without Evidence of Clostridium Difficile (Toxins)</title>
          <units>episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="246"/>
                <count group_id="O2" value="231"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.80</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>1.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.93</p_value>
            <p_value_desc>adjusting for age, sex, CRP, leukocyte count, duration of antibiotic treatment, and administration of antibiotics</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.53</ci_lower_limit>
            <ci_upper_limit>2.03</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence Density of Antibiotic-associated Diarrhea</title>
        <time_frame>29 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Saccharomyces Boulardii</title>
            <description>Participants received Saccharomyces boulardii 250 mg capsules twice per day within 24 hours of initiating antibiotic treatment and continued treatment for 7 days after antibiotic discontinuation
Saccharomyces boulardii: Units: 500 mg per day Route of administration : Oral Use Hard-Capsule</description>
          </group>
          <group group_id="O2">
            <title>Microcristallin Cellulose</title>
            <description>Participants received matching placebo twice per day within 24 hours of initiating antibiotic treatment and continued treatment for 7 days after antibiotic discontinuation
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Density of Antibiotic-associated Diarrhea</title>
          <units>cases per year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="246"/>
                <count group_id="O2" value="231"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.78"/>
                    <measurement group_id="O2" value="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6</p_value>
            <p_value_desc>Association between initial leukocyte count and incidence of AAD</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.653</p_value>
            <p_value_desc>Association between the initial C-reactive protein and incidence of AAD</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.00</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Duration of Antibiotic-associated Diarrhoea and Clostridium Difficile-associated Diarrhea</title>
        <time_frame>29 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Saccharomyces Boulardii</title>
            <description>Participants received Saccharomyces boulardii 250 mg capsules twice per day within 24 hours of initiating antibiotic treatment and continued treatment for 7 days after antibiotic discontinuation
Saccharomyces boulardii: Units: 500 mg per day Route of administration : Oral Use Hard-Capsule</description>
          </group>
          <group group_id="O2">
            <title>Microcristallin Cellulose</title>
            <description>Participants received matching placebo twice per day within 24 hours of initiating antibiotic treatment and continued treatment for 7 days after antibiotic discontinuation
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Average Duration of Antibiotic-associated Diarrhoea and Clostridium Difficile-associated Diarrhea</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="246"/>
                <count group_id="O2" value="231"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.48" spread="4.13"/>
                    <measurement group_id="O2" value="4.26" spread="3.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Number of Bowel Movements in Patients With Antibiotic-associated Diarrhoea and Clostridium Difficile-associated Diarrhea</title>
        <time_frame>29 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Saccharomyces Boulardii</title>
            <description>Participants received Saccharomyces boulardii 250 mg capsules twice per day within 24 hours of initiating antibiotic treatment and continued treatment for 7 days after antibiotic discontinuation
Saccharomyces boulardii: Units: 500 mg per day Route of administration : Oral Use Hard-Capsule</description>
          </group>
          <group group_id="O2">
            <title>Microcristallin Cellulose</title>
            <description>Participants received matching placebo twice per day within 24 hours of initiating antibiotic treatment and continued treatment for 7 days after antibiotic discontinuation
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Average Number of Bowel Movements in Patients With Antibiotic-associated Diarrhoea and Clostridium Difficile-associated Diarrhea</title>
          <units>bowel movements per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="246"/>
                <count group_id="O2" value="231"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.48" spread="3.82"/>
                    <measurement group_id="O2" value="4.07" spread="3.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Discontinuation or Change of Initially Prescribed Antibiotic</title>
        <time_frame>29 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Saccharomyces Boulardii</title>
            <description>Participants received Saccharomyces boulardii 250 mg capsules twice per day within 24 hours of initiating antibiotic treatment and continued treatment for 7 days after antibiotic discontinuation
Saccharomyces boulardii: Units: 500 mg per day Route of administration : Oral Use Hard-Capsule</description>
          </group>
          <group group_id="O2">
            <title>Microcristallin Cellulose</title>
            <description>Participants received matching placebo twice per day within 24 hours of initiating antibiotic treatment and continued treatment for 7 days after antibiotic discontinuation
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Discontinuation or Change of Initially Prescribed Antibiotic</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="246"/>
                <count group_id="O2" value="231"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Ten participants did not take trial drug and were excluded from the safety analysis population. Therefore, the numbers of participants at risk are 245 and 222, while the numbers in the participant flow are 246 and 231.</desc>
      <group_list>
        <group group_id="E1">
          <title>Saccharomyces Boulardii</title>
          <description>Participants received Saccharomyces boulardii 250 mg capsules twice per day within 24 hours of initiating antibiotic treatment and continued treatment for 7 days after antibiotic discontinuation
Saccharomyces boulardii: Units: 500 mg per day Route of administration : Oral Use Hard-Capsule</description>
        </group>
        <group group_id="E2">
          <title>Microcristallin Cellulose</title>
          <description>Participants received matching placebo twice per day within 24 hours of initiating antibiotic treatment and continued treatment for 7 days after antibiotic discontinuation
Placebo: Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Duodenal perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>Pulmonary empyema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>Gastrointestinal sounds abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>Faecal incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>Glossodynia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Stephan Ehrhardt</name_or_title>
      <organization>Johns Hopkins Bloomberg School of Public Health</organization>
      <phone>410-502-3872</phone>
      <email>sehrhard@jhsph.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

